Bioporto (One-pager): From Diagnostic innovator to Diagnostic company
Key investment reasons
Having recently received a marketing authorization (FDA approval) of the ProNephro AKI for pediatric use in the US, and announced a collaboration with leading test analyzer provider Roche, as well as, the current ongoing use of the NGAL Test in Europe, BioPorto has the potential to successfully launch ProNephro AKI/NGAL Test for pediatrics globally.
The grant of a marketing authorization of the ProNephro AKI for pediatrics can act as a lever to open up for adult use and other addressable markets totalling up to USD 3 billion annually, growing 4% as the use of the NGAL Test could be broadened to other settings and geographical areas than hospitals in US.
At the moment, there are no competing NGAL tests commercially available in the US, and BioPorto has already de-risked its commercial potential as they currently generate revenue.
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Henrik Ekman 08:15 AM 04-03-2024
Login required
This content is only available for logged in users
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read more on company page